<div id="readability-page-1"><div><p><span>Gilead Sciences Inc </span><span>:</span></p><ul><li>NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PHASE 3 ASCENT-04/KEYNOTE-D19 RESULTS SUPPORTING TRODELVY® PLUS KEYTRUDA® AS A POTENTIAL NEW STANDARD OF CARE IN FIRST-LINE PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER</li></ul></div></div>

<p>Gilead Sciences Inc :NEW ENGLAND JOURNAL OF MEDICINE PUBLISHES PHASE 3 ASCENT-04/KEYNOTE-D19 RESULTS SUPPORTING TRODELVY® PLUS KEYTRUDA® AS A POTENTIAL NEW STANDARD OF CARE IN FIRST-LINE PD-L1+ METASTATIC TRIPLE-NEGATIVE BREAST CANCER</p>

Reuters

Invesco Nasdaq Biotechnology ETF

SPDR S&P Biotech

Invesco Biotechnology & Genome ETF

iShares Biotechnology ETF

Proshares Ultra Nasdaq Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Gilead Sciences

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

VanEck Biotech ETF

New England Journal Of Medicine Publishes Phase 3 Ascent-04/Keynote-D19 Results